The ‘Global Transthyretin Amyloidosis Treatment Market Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global transthyretin amyloidosis treatment market share, assessing the market on the basis of its segments like drug type, disease type, distribution channel, and major region.

The report studies the latest updates in the market, along with their impact across the market. It also analysis the market demand, together with its price and demand indicators. The report also tracks the market on the bases of SWOT and Porter’s Five Forces Models.

Transthyretin Amyloidosis Treatment Market Size, Share, Price, Growth, Trends, Industry Report, Key Player, Major Segments and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

• • Forecast CAGR (2023-2031): 15%

It is projected that the prevalence of transthyretin amyloidosis will drive the transthyretin Amyloidosis Treatment Market expansion. The development of numerous new treatments and the availability of potent medications in the pipeline to treat transthyretin are some of the key factors that are contributing to the market growth.

Get a Free Sample Report with Table of Contents@ https://www.expertmarketresearch.com/reports/transthyretin-amyloidosis-treatment-market/requestsample

Over the forecast period, it is expected that the prevalence of transthyretin amyloidosis would rise due to the expanding geriatric population in the world. Transthyretin amyloidosis diagnoses among cardiomyopathy patients and the ageing patient population are both anticipated to fuel the market expansion.

Government and community initiatives to increase public understanding of transthyretin amyloidosis treatment are anticipated to stimulate market expansion. Additionally, the rise of the transthyretin amyloidosis treatment market during the course of the projected period is due to the sector’s expanding healthcare infrastructure, countries’ faster economic growth, and a significant advancement in diagnostic techniques.

North America dominated the market in the historical period and the region is anticipated to maintain its dominance during the forecast period. The global transthyretin amyloidosis treatment market expansion in the region is influenced by factors such as rising novel medicine prescription, adequate reimbursement policies, and increased treatment rates in the area. A significant market driver in the region is the launch of novel medicines.

Read Full Report with Table of Contents@ https://www.expertmarketresearch.com/reports/transthyretin-amyloidosis-treatment-market

Transthyretin Amyloidosis Treatment Industry Definition and Major Segments

A protein abnormality called transthyretin amyloidosis has an impact on the heart’s pumping mechanism. In this illness, fibrils, which are irregular proteins, accumulate in the heart. Regular blood flow is hampered by the hardening of the left ventricle and the major pumping segment brought on by these proteins. Other names for this condition include cardiac amyloidosis, ATTR amyloidosis, and TTR amyloidosis.

Based on drug type, the market is segmented into:

• • Tafamidis

• • Diflunisal

• • Patisiran

• • Inotersen

• • Others

The market on the basis of disease type is divided into:

• • Hereditary Type Transthyretin Amyloidosis
    • • Polyneuropathy
    • • Cardiomyopathy
    • • Mixed Type

• • Wild Type Transthyretin Amyloidosis

The market on the basis of distribution channel is segmented into:

• • Hospital Pharmacies

• • Online Pharmacies

• • Retail Pharmacies

On the basis of region, the market is divided into:

• • North America

• • Europe

• • Asia Pacific

• • Latin America

• • Middle East and Africa

Transthyretin Amyloidosis Treatment Market Trends

Government and non-government organisations’ efforts to raise public knowledge of the condition and the advantages of its treatments, supported by patient reimbursements, are anticipated to increase the rate of early disease identification and, consequently, treatment.

Also, government requirements for vital healthcare services, faster approvals for key pharmaceuticals, and sanctions in emergency healthcare protocols are helping in the transthyretin amyloidosis treatment market expansion. In addition, minimising treatment interruptions was suggested for these patients due to the difficulty in maintaining their therapy. This is boosting the growth of the transthyretin amyloidosis market, along with the rising availability of novel medications by key manufacturers.

Hospital pharmacies captured the largest revenue share. Majority of hospitals are focusing on the disease’s diagnosis, research, and treatment, which is accelerating the segment’s growth. Due to patients’ simple access to medications, which is also increasing the use to obtain health information, online pharmacies are predicted to experience the fastest increase during the forecast period. This will further increase the transthyretin amyloidosis treatment market growth.

The forecast period is expected to witness robust growth in the hereditary transthyretin amyloidosis segment because more people with co-morbidities die, increasing the need for hereditary transthyretin amyloidosis treatment. This is predicted to increase the patient pool, which will support the segment’s growth, along with growing awareness by experts of the importance of people seeking diagnosis for rare diseases such as transthyretin amyloidosis.

Key Market Players

The major players in the global transthyretin amyloidosis treatment market report are:

• • Sorrento Therapeutics, Inc.

• • Astellas Pharma Inc.

• • AstraZeneca plc

• • Alexion Pharmaceuticals, Inc.

• • Spectrum Pharmaceuticals, Inc.

• • Pfizer Inc.

• • Alnylam Pharmaceuticals, Inc.

• • Ionis Pharmaceuticals, Inc.

• • Eidos Therapeutics, Inc.

• • Corino Therapeutics, Inc.

• • Prothena Corporation plc

The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight Corporation
Contact Person: Steven Luke, Corporate Sales Specialist – U.S.A.
Email: [email protected]
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

The post Global Transthyretin Amyloidosis Treatment Market Size to Grow at a CAGR of 15% During the Forecast Period of 2023-2031 appeared first on Market Research Report.